This chart lays out non-clear cell response rates for two kidney cancer clinical trials that were presented at ASCO-GU 2019. The Keynote 427 trial for pembrolizumab (Keytruda) as monotherapy and the Calypso trial combining savolitinib (MET inhibitor) and durvalumab (PD-1 inhibitor).
Non-clear-cell-chartNon-Clear Cell Response Rate Chart
